XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:        
Research and development $ 2,763,000 $ 2,983,000 $ 9,690,000 $ 9,698,000
General and administrative 2,213,000 2,245,000 8,544,000 10,238,000
Total operating expenses 4,976,000 5,228,000 18,234,000 19,936,000
Operating loss (3,299,000) (4,722,000) (13,321,000) (19,712,000)
Other income (expense):        
Interest income 72,000 51,000 400,000 147,000
Interest expense (34,000) (134,000) (395,000) (711,000)
Change in fair value of liability instruments     0 1,000
Total other expense 38,000 (83,000) 5,000 (563,000)
Net loss $ (3,261,000) $ (4,805,000) $ (13,316,000) $ (20,275,000)
Net loss per share, basic $ (0.75) $ (2.07) $ (4.24) $ (11.58)
Net loss per share, diluted $ (0.75) $ (2.07) $ (4.24) $ (11.58)
Basic weighted average shares used in calculating net loss per share attributable to common stockholders 4,321,731 2,320,017 3,140,925 1,750,350
Diluted weighted average shares used in calculating net loss per share attributable to common stockholders 4,321,731 2,320,017 3,140,925 1,750,350
Grant [Member]        
Revenue $ 1,677,000 $ 506,000 $ 4,913,000 $ 224,000